In CRC patients, CD163+ TAM expression was significantly higher in stages III–IV compared with I–II (P < 0.05), in those with lymph node metastases (P < 0.05), and in patients with low tumor differentiation (P < 0.05). This evidence concerns the gene CD163 and colorectal carcinoma.